An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
- PMID: 21687579
- PMCID: PMC3114080
- DOI: 10.1155/2011/820816
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
Abstract
Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients' quality of life. Antimuscarinics are generally well tolerated with mild and predictable side effects. Available antimuscarinics have small, yet statistically significant, differences in their efficacy and tolerability profiles. In clinical practice, finding the agent that offers the optimum balance of efficacy and side effects for an individual patient remains the major challenge.
References
-
- Hashim H, Abrams P. Overactive bladder: an update. Current Opinion in Urology. 2007;17(4):231–236. - PubMed
-
- Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. European Urology. 2011;59(3):377–386. - PubMed
-
- Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourology and Urodynamics. 2010;29(1):112–115. - PubMed
-
- Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83(5):259–269. - PubMed
-
- Andersson KE, Chappie CR. Oxybutynin and the overactive bladder. World Journal of Urology. 2001;19(5):319–323. - PubMed
LinkOut - more resources
Full Text Sources
